Phase 3 N=134 Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient
Hypertension
Primary: Change in Systolic Blood Pressure From Baseline of the Preceding Study — 148.8; 148.8; 148.8; -8.7 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=271 Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
Dyslipidemia
Primary: Flushing ASsessment Tool (FAST) Test-retest Reliability--mean Flushing Severity Score — 0.75 Intraclass correlation coefficient
Phase 3 N=1,283 Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
Infections, Papillomavirus
Primary: Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)…
Phase 3 N=1,007 Tiotropium / Respimat One-Year Study
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 After 48 Weeks — 0.077; 0.105; -0.036 Litres — p=<0.0001
Phase 3 N=833 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
Hypercholesterolemia · Coronary Heart Disease · Atherosclerosis
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment — -59.7200; -63.4800; -55.2200; -57.4200 Percentage
Phase 3 N=983 Tiotropium / Respimat One-Year Study
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough FEV1 at Week 48, Full Analysis Set - Clinic Spirometry (FAS-PFT) — 0.097; 0.116; -0.046 Litres — p=<0.0001
Phase 3 N=1,053 Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at Week 6 — -26.7; -12.8 Percent Change — p=<0.001
Phase 3 N=908 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Phase 3 N=451 A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
Diabetic Neuropathy
Primary: Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator. — 11; 52; 74; 196 Participants
Phase 3 N=652 Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 13 or the Last Post-baseline Assessment — -8.0; -11.6; -13.2; -2.9 Scores on a…
Phase 3 N=862 Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis
Chronic Allergic Rhinitis · Nonallergic Rhinitis
Primary: Number of Participants Reporting Adverse Events — 207; 211 Participants
Phase 3 N=263 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Cataract Extraction
Primary: Resolution of Post Operative Inflammation — 58.0; 27.3 % of participants with a score of 0
Phase 3 N=629 E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
Heartburn
Primary: Complete Heartburn Relief During the First Full 24-Hour Period in the ITT Population. — 114; 163 participants — p=<0.001
Phase 3 N=248 A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery
Cataract Extraction · Pain · Inflammation
Primary: Resolution of Post Operative Inflammation — 46.3; 25.6 % of participants with a score of 0
Phase 3 N=207 Phase 3 Clinical Trial of Teriparatide in Japan
Osteoporosis
Primary: Percent Change in Bone Mineral Density at Lumbar Spine (L2-L4) — 9.82; 0.04 percent change in BMD — p=<0.001